AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C.
It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia.
Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses.
AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; and Voluntis. The company was incorporated in 2012 and is based in North Chicago, Illinois.
What is AbbVie’s stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol “ABBV.”
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Monday, November 5th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $1.07 per share on Friday, February 15th. This represents a $4.28 dividend on an annualized basis and a dividend yield of 4.85%. The ex-dividend date of this dividend is Monday, January 14th. This is a boost from AbbVie’s previous quarterly dividend of $0.96. View AbbVie’s Dividend History.
How will AbbVie’s stock buyback program work?
AbbVie declared that its Board of Directors has initiated a stock repurchase plan on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its stock is undervalued.
How were AbbVie’s earnings last quarter?
AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, November, 2nd. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.01 by $0.13. The firm earned $8.24 billion during the quarter, compared to analyst estimates of $8.23 billion. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The firm’s revenue was up 17.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.41 earnings per share.
When is AbbVie’s next earnings date?
AbbVie is scheduled to release their next quarterly earnings announcement on Friday, January 25th 2019.
How can I listen to AbbVie’s earnings call?
AbbVie will be holding an earnings conference call on Friday, January 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has AbbVie issued on next quarter’s earnings?
AbbVie issued an update on its FY18 earnings guidance on Friday, November, 2nd. The company provided EPS guidance of $7.90-7.92 for the period, compared to the Thomson Reuters consensus estimate of $7.88.
What price target have analysts set for ABBV?
18 brokers have issued 1-year price targets for AbbVie’s shares. Their forecasts range from $65.61 to $144.00. On average, they anticipate AbbVie’s share price to reach $100.4813 in the next year. This suggests a possible upside of 13.8% from the stock’s current price.
What is the consensus analysts’ recommendation for AbbVie?
18 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for AbbVie in the last year. There are currently 4 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of “Hold.”
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, “AbbVie’s key drug, Humira has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential. Mavyret’s launch has also been stronger than expected. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. Moreover, AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. AbbVie’s shares have outperformed the industry in the past one month. However, direct biosimilar competition to Humira in Europe from October can erode revenues in 2019. Nonetheless, estimates have gone up ahead of Q4 earnings. AbbVie has a positive record of earnings surprises in the recent quarters.” (1/8/2019)
- 2. BMO Capital Markets analysts commented, “On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018.” (2/15/2018)
Has AbbVie been receiving favorable news coverage?
Media headlines about ABBV stock have trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a news sentiment score of 0.6 on InfoTrie’s scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
Who are AbbVie’s key executives?
AbbVie’s management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
- Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 56)
- Mr. Michael E. Severino, Vice Chairman & Pres (Age 53)
- Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
- Ms. Laura J. Schumacher, Vice Chairman and External Affairs & Chief Legal Officer (Age 56)
Who are AbbVie’s major shareholders?
AbbVie’s stock is owned by a number of of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.08%), Gulf International Bank UK Ltd (0.02%), Welch Group LLC (0.02%), Park National Corp OH (0.02%), State of Alaska Department of Revenue (0.02%) and CENTRAL TRUST Co (0.01%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase.
Which major investors are selling AbbVie stock?
ABBV stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Bainco International Investors, Chesley Taft & Associates LLC, Kessler Investment Group LLC, Private Trust Co. NA, Chicago Partners Investment Group LLC, CENTRAL TRUST Co and New England Research & Management Inc.. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase.
Which major investors are buying AbbVie stock?
ABBV stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Lynch & Associates IN, Park National Corp OH, Fulton Bank N.A., Adams Asset Advisors LLC, Welch Group LLC, Ellenbecker Investment Group and State of Alaska Department of Revenue. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie’s stock price today?
One share of ABBV stock can currently be purchased for approximately $88.31.
How big of a company is AbbVie?
AbbVie has a market capitalization of $132.09 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.
What is AbbVie’s official website?
The official website for AbbVie is http://www.abbvie.com.
How can I contact AbbVie?
AbbVie’s mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.